Immunotherapy in Lung Cancer
Podcast 2021030
Questions:
- What is the role of immunotherapy in PD-L1 negative mNSCLC?
- Could you describe the rational for cases with negative PDL1 responding to immunotherapy?
- What about liquid PDL-1 assay and how to be implemented in clinical practice?
- How long the duration required for re-exposition to previously received immunotherapy?
- Patients with history of auto-immune diseases, there are any criteria to select the patient who will be candidate to receive immunotherapy or not?
Expert
/attachment.e-eso.net%2F48%2F700.jpg)
Institut Curie
Paris, France
Paris, France
04
Nov 2021
